Lightpoint Medical reported on Tuesday the receipt of the CE Mark approval for the launch of the world's first robotic gamma probe SENSEI across hospitals in Europe for intra-operative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system.
The company said the SENSEI technology promises more precise, targeted cancer surgery and is applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynecological and prostate cancer.
According to the company, SENSEI locates SPECT radioligands including 99mTc-nanocolloid for sentinel lymph node detection or cancer-targeted drugs for cancer metastasis detection such as 99mTc-PSMA (Prostate Specific Membrane Antigen) in prostate cancer surgery.
In addition, the SENSEI promises accurate real-time cancer detection for robot-assisted cancer surgery. Currently, surgeons have no way to precisely detect cancer intra-operatively. The device was successfully registered with the US FDA in September 2020.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review